Non-invasive detection kit for early diagnosis of Alzheimer’s Disease


Alzheimer’s disease (AD) is the most common form of dementia accounting for over 70-80% of the cases and affecting 50 millions of people worldwide. This technology provides a cost-effective, simple, direct yet sensitive platform for early neurodegenerative diseases detection and diagnostics.

  • Non-invasive detection kit for early diagnosis of Alzheimer’s Disease 0
  • Non-invasive detection kit for early diagnosis of Alzheimer’s Disease 1
Commercialisation opportunities
Seeking partners to collaborate and bring this to clinical trials
Problem addressed

Several biomarkers in cerebrospinal fluid (CSF) have been recognized and established for AD diagnosis with high diagnostic accuracy over 85%. However, the collection of CSF is invasive and causes discomfort and side effects on patients. This technology provides a non-invasive solution for early Alzheimer’s disease diagnosis.

  • The detection assay is an immunocomplex based approach with magnetic nanoprobe for sensitive detection of the target biomarker in different body fluids including blood serum, saliva and urine.
  • In addition, the detection assay has a wide dynamic range that allows the quantification of biomarkers in a minute amount (a few microliters) of samples.
Key impact
  • It is a non-invasive, simple and cost-effective alternative for accurate diagnosis of Alzheimer’s disease.
  • The detection kit is more sensitive than the commercially available ELISA kit. The diagnostic tools could provide a practical platform for population-wide screening for neurodegenerative diseases.
  • This detection assay is highly sensitive and capable of measuring the content of biomarkers in saliva or urine.
  • It can potentially serve as a point-of-care tool for the diagnosis of AD.
  • Act as a monitoring tool to measure the subtle changes in the expression profile of disease-associated biomarkers


  • US Patent No. US 10,739,336
  • US Patent No. US 9,795,694
Hong Kong Baptist University (HKBU)

Aspiring to be a leading, research-led, liberal arts University in Asia, Hong Kong Baptist University is committed to conducting world-leading investigations that extends the frontiers of knowledge, tackles global challenges and benefits the community at home and abroad. 

Pursuing research excellence is one of the priorities of the University’s Institutional Strategic Plan 2018-2028. The University keeps enhancing its capacity and strength to produce world-class research with an aim to bring significant impact to the society.